Printer Friendly

-Swedish Moberg Derma Q2 loss widens due to bigger costs.

NORDIC BUSINESS REPORT-August 12, 2011--Swedish Moberg Derma Q2 loss widens due to bigger costs(C)2011 M2 COMMUNICATIONS http://www.m2.com

12 August 2011 - Swedish pharma company Moberg Derma AB (STO:MOB) said today its second-quarter net loss widened to SEK9.6m from SEK8m a year earlier as a big increase in revenue was outweighed by even higher costs.

Revenue amounted to SEK8m in April-June 2011, up from SEK219,000. However, costs of goods sold surged to SEK4.3m from SEK60,000. Research and development (R&D) costs grew to SEK7.1m from SEK4.9m, and expenses for marketing and administration also increased.

As a result, the operating loss widened to SEK9.7m from SEK8m.

This was Moberg Derma's first quarter as a listed company. The firm floated on the Nasdaq OMX Nordic exchange in Stockholm on 26 May after a new share issue that brought net proceeds of SEK69.2m.

In the first half of 2011, Moberg Derma saw its net loss expand to SEK16.2m from SEK12.7m a year earlier although revenue surged to SEK13.5m from SEK823,000.

(EUR1 = SEK9.3)

((Comments on this story may be sent to info@m2.com)).END.PUB430>PDAugust 12, 2011>JNNORDIC BUSINESS REPORT.PRICEDATENOT APPLICABLE.DAY

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Nordic Business Report
Article Type:Financial report
Date:Aug 12, 2011
Words:208
Previous Article:-Pronova BioPharma plans to start phase I trials with lipid-derived drug.
Next Article:-Brokers lower price targets on Novozymes after Q2.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters